Abstract: The present technology relates to an electronic device. A computing system may include a host and a peripheral component interconnect express (PCIe) device connected the host through a link. The host comprises a host memory and a storage device driver. The host memory may store information on a first target command to be executed in the PCIe device. The storage device driver may provide the first target command to the host memory and a notification message indicating that the first target command is stored in the host memory to the PCIe device. The PCIe device may request the host memory to register an address of the host memory in which a second target command to be executed in the PCIe device is stored through a preset protocol.

Abstract: Provided are a Peripheral Component Interconnect Express (PCIe) interface device and a method of operating the same. The PCIe interface device may include a performance analyzer and a traffic class controller. The performance analyzer may be configured to measure throughputs of multiple functions executed on one or more Direct Memory Access (DMA) devices. The traffic class controller may be configured to allocate traffic class values to transaction layer packets received from the multiple functions based on the throughputs of the multiple functions.

Abstract: Provided are a Peripheral Component Interconnect Express (PCIe) device and a method of operating the same. The PCIe device may include a performance analyzer, a delay time information generato and a command fetcher. The performance analyzer may measure throughputs of a plurality of functions, and generate throughput analysis information indicating a comparison result between the throughputs of the plurality of functions and throughput limits corresponding to the plurality of functions. The delay time information generator may generate a delay time for delaying a command fetch operation for each of the plurality of functions based on the throughput analysis information. The command fetcher may fetch a target command from a host based on a delay time of a function corresponding to the target command.

Abstract: Embodiments of the present disclosure relate to a memory system and an operating method of the memory system. According to embodiments of the present disclosure, a memory system may include a buffer memory for storing tail doorbell information for N submission queues capable of storing a command fetched from the host or head doorbell information for N completion queues capable of storing an execution result of the command fetched from the host.

Abstract: The present invention relates to a method for the synthesis of 2,5-furandicarboxylic acid, and more specifically, the present invention relates to a more efficient and economical method capable of preparing 2,5-furandicarboxylic acid having various functions with high purity and high yield, even without using a transition metal catalyst.

Abstract: The present invention relates to a metal oxide powder, a method of preparing the same, and a lithium secondary battery using the same, which comprises: a metal oxide powder is represented by Formula (1), Lix(M1-m-zAmDz)Ot??Formula (1) in the above Formula (1), 0.85?x?1.2, 0?m?0.01, 0<z?0.04, 1.85?t?2.2, M is selected from the group consisting of Ni, Co, Mn and combinations thereof, A is selected from the group consisting of Mg, Ca, Sr, Ba and combinations thereof, D is selected from the group consisting of Ti, Zr, Ce, Ge, Sn and combinations thereof, and E is an average oxidation number of A and D, and E>3.5.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands a disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: There are provided a cathode active material for a lithium secondary battery, a method of preparing the same, and a lithium secondary battery containing the same. The cathode active material for a lithium secondary battery includes: a compound reversibly intercalating and deintercalating lithium; and a coating layer positioned on at least a portion of a surface of the compound, wherein the coating layer is a composite coating layer containing Li3PO4 and further containing a lithium metal oxide, a metal oxide, and/or a combination thereof, the lithium metal oxide or the metal oxide containing Zr.

Abstract: A method of charging a secondary battery and a charging device that can improve stability and extend the life span of the battery. When the secondary battery includes a plurality of cells, the charging method is changed when a voltage imbalance from 100 mV to 300 mV occurs among the cells. In that range, the charging method changes from a constant current-constant voltage charging method to a pulse-charging method. When the voltage imbalance is 300 mV or more, the electricity path is blocked, shutting down the battery. When the voltage imbalance is 100 mV or less, the constant current-constant voltage charging method is maintained. The method and device also stop charging when the battery reaches full charge.

Abstract: An apparatus and method for modular multiplication. The modular multiplication apparatus includes a first operation unit for performing a first operation based on a structure of at least one of a serial multiplier and a serial squarer-based multiplier; a second operation unit for performing a second operation based on a structure of at least one of the serial multiplier and the serial squarer-based multiplier; an adder unit for outputting the sum of results of the first operation and the second operation, inputting an intermediate value stream to the first input unit, which calculates the product of the intermediate value stream and a zeta parameter, and outputting a High-Order Term as a result of Montgomery Modular Multiplication, wherein the first and second operation units output a result in digit-serial format in order from the least significant digit to the most significant digit.

Abstract: The present invention relates to a metal oxide powder, a method of preparing the same, and a lithium secondary battery using the same, which comprises: a metal oxide powder is represented by Formula (1), Lix(M1-m-zAmDz)Ot??Formula (1) in the above Formula (1), 0.85?x?1.2, 0?m?0.01, 0<z?0.04, 1.85?t?2.2, M is selected from the group consisting of Ni, Co, Mn and combinations thereof, A is selected from the group consisting of Mg, Ca, Sr, Ba and combinations thereof, D is selected from the group consisting of Ti, Zr, Ce, Ge, Sn and combinations thereof, and E is an average oxidation number of A and D, and E>3.5.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: There are provided a cathode active material for a lithium secondary battery, a method of preparing the same, and a lithium secondary battery containing the same. The cathode active material for a lithium secondary battery includes: a core made of a compound reversibly intercalating and deintercalating lithium; and a coating layer positioned on at least a portion of a surface of the compound, wherein the coating layer is a composite coating layer containing Li3PO4 and LiF, and further containing a lithium metal compound, a metal oxide, a metal fluoride compound, and/or a combination thereof, and the core is doped with fluorine.

Abstract: An apparatus and method for modular multiplication. The modular multiplication apparatus includes a first operation unit for performing a first operation based on a structure of at least one of a serial multiplier and a serial squarer-based multiplier; a second operation unit for performing a second operation based on a structure of at least one of the serial multiplier and the serial squarer-based multiplier; an adder unit for outputting the sum of results of the first operation and the second operation, inputting an intermediate value stream to the first input unit, which calculates the product of the intermediate value stream and a zeta parameter, and outputting a High-Order Term as a result of Montgomery Modular Multiplication, wherein the first and second operation units output a result in digit-serial format in order from the least significant digit to the most significant digit.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.